Posted by Michael Wonder on 30 Jan 2018
Post-market review of chronic obstructive pulmonary disease medicines – final report released
30 January 2018 - The final report and outcomes of the post-market review of chronic obstructive pulmonary disease medicines is now available.
In August 2015, the PBAC recommended a post-market Review of COPD Medicines, noting that a number of new combinations, including long-acting muscarinic antagonist (LAMA)/LABA and LABA/inhaled corticosteroid (ICS) combinations, have been listed recently on the PBS and that there was concern about use of multiple products.
The report, including PBAC sub-committee advice and stakeholder comments, was provided to the PBAC for consideration in August 2017. The PBAC Minutes and final report for this item are now available. Parts of the PBAC minutes have been redacted due to ‘commercial-in-confidence’ information.
